Ken Griffin Vista Gen Therapeutics, Inc. Transaction History

Citadel Advisors LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$0.12 - $0.3 $25,419 - $63,549	-211,833 Reduced 92.3%	17,674 $2,000
Q4 2022 Feb 14, 2023	BUY	$0.09 - $0.16 $11,412 - $20,289	126,809 Added 123.48%	229,507 $22,000
Q3 2022 Nov 14, 2022	SELL	$0.14 - $1.07 $166,359 - $1.27 Million	-1,188,285 Reduced 92.04%	102,698 $16,000
Q2 2022 Aug 15, 2022	BUY	$0.88 - $1.73 $216,627 - $425,870	246,168 Added 23.56%	1,290,983 $1.14 Million
Q1 2022 May 16, 2022	BUY	$1.14 - $2.09 $1.04 Million - $1.9 Million	908,821 Added 668.28%	1,044,815 $1.3 Million

Q4 2021 Feb 14, 2022	BUY	$1.67 - $2.76 $16,472 - $27,224	9,864 Added 7.82%	135,994 $0
Q3 2021 Nov 15, 2021	BUY	$2.62 - $3.45 $299,138 - $393,903	114,175 Added 955.04%	126,130 $346,000
Q2 2021 Aug 16, 2021	SELL	$1.96 - $3.15 $188,640 - $303,171	-96,245 Reduced 88.95%	11,955 $0
Q1 2021 May 17, 2021	BUY	$1.89 - $2.96 $175,794 - $275,318	93,013 Added 612.45%	108,200 $230,000
Q2 2018 Aug 10, 2018	BUY	$0.85 - $1.5 $12,908 - $22,780	15,187 New	15,187 $0
Q4 2017 Feb 09, 2018	SELL	$0.72 - $2.03 $9,640 - $27,181	-13,390 Closed	0 $0
Q3 2017 Nov 09, 2017	BUY	$1.54 - $1.85 $20,620 - $24,771	13,390	13,390 $21,000

2.7M

Ticker VTGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 206,836,000
Market Cap $720M
Description
VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in Phase III d...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.